Opdualag

relatlimab and nivolumab

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for Opdualag, covering 2022-03-18 to 2026-07-21. Get the full timeline:

Most recent: EMA Authorised: Opdualag (nivolumab;relatlimab) — Bristol-Myers Squibb Pharma EEIG